Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

被引：0
作者：
Guntulu Ak
Yuji Tada
Hideaki Shimada
Selma Metintas
Masaaki Ito
Kenzo Hiroshima
Masatoshi Tagawa
Muzaffer Metintas
机构：
[1] Eskisehir Osmangazi University,Department of Chest Diseases, Medical Faculty, Lung and Pleural Cancers Research and Clinical Center
[2] Chiba University,Department of Respirology, Graduate School of Medicine
[3] Toho University,Department of Surgery, School of Medicine
[4] Lung and Pleural Cancers Research and Clinical Center,Department of Public Health, Medical Faculty
[5] Eskisehir Osmangazi University,Department of Clinical Oncology, School of Medicine
[6] Toho University,Department of Pathology
[7] Tokyo Women’s Medical University,Department of Molecular Biology and Oncology, Graduate School of Medicine
[8] Yachiyo Medical Center,undefined
[9] Division of Pathology and Cell Therapy,undefined
[10] Chiba Cancer Center Research Institute,undefined
[11] Chiba University,undefined
来源：
BMC Cancer | / 17卷
关键词：
Mesothelioma; Mesothelin; Midkine; Prognosis; Biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 300 条
  • [21] Roggli V(2007)Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma Chest 132 1239-1549
  • [22] Travis WD(2009)Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesohtleioma Clin Biochem 42 1046-954
  • [23] Wick M(2012)Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool PLoS One 7 e46091-3322
  • [24] Robinson BW(2012)Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis J Clin Oncol 30 1541-1937
  • [25] Creaney J(2009)Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment Am J Respir Crit Care Med 179 950-498
  • [26] Lake R(2010)Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma J Clin Oncol 28 3316-1182
  • [27] Nowak A(2010)Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma J Thorac Oncol 6 1930-1305
  • [28] Musk AW(2014)A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice BMC Cancer 14 674-873
  • [29] de Klerk N(2013)Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma Lung Cancer 82 491-638
  • [30] Winzell P(2015)The south west area mesothelioma and pemetrexed trial: a multicentre propective observational study evaluating novel markers of chemotherapy response and prognostication Br J Cancer 112 1175-undefined
12345678910